InChI |
InChI=1S/C74H108N14O17/c1-40(2)31-52(64(94)84-59(39-90)68(98)85-58(38-89)67(97)83-57(74(104)105)33-42(5)6)80-71(101)62(43(7)8)86-70(100)61-19-14-30-88(61)73(103)56(36-46-37-77-51-17-10-9-15-49(46)51)82-66(96)54(35-45-22-26-48(92)27-23-45)79-69(99)60-18-13-29-87(60)72(102)55(32-41(3)4)81-65(95)53(34-44-20-24-47(91)25-21-44)78-63(93)50(76)16-11-12-28-75/h9-10,15,17,20-27,37,40-43,50,52-62,77,89-92H,11-14,16,18-19,28-36,38-39,75-76H2,1-8H3,(H,78,93)(H,79,99)(H,80,101)(H,81,95)(H,82,96)(H,83,97)(H,84,94)(H,85,98)(H,86,100)(H,104,105)/t50-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-/m0/s1
|
Reference |
- KYL was also shown to prevent growth cone collapse in chicken retinal explants and dissociated cultures of rat cortical neurons, promote nerve regeneration and functional recovery in a rat model of spinal cord injury, and inhibit the adhesion of human T-cells to endothelial cells. Thus, KYL can target human, mouse, rat and chicken EphA4 and may be useful for promoting nerve regeneration after injury and modulating immune responses.
- Distinctive Binding of Three Antagonistic Peptides to the Ephrin-Binding Pocket of the EphA4 Receptor
- STI and KYL inhibitors prevented AβO-induced dendritic spine loss. Although the absence of EphA4 did not completely rescue the dendritic spine loss, EphA4-knockout neurons show a significant decrease in AβO-induced dendritic spine loss. Furthermore, protection was observed in mature neurons (with established synapses) transfected with either c-Abl shRNA or EphA4 shRNA.
- EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid-β oligomers
|